icon-folder.gif   Conference Reports for NATAP  
  59th Annual Meeting of the American Association
for the Study of Liver Diseases
Oct 31-Nov 1 2008
San Francisco, CA
Back grey_arrow_rt.gif
Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection
  Reported by Jules Levin
AASLD Nov 3 2008 San Francisco, CA
Eric Lawitz1, Mark Sulkowski2, Ira Jacobson3, Shaban Faruqui4, Walter Kraft5, Benedict Maliakkal6, Mohamed Al-Ibrahim7, Reem Ghalib8, Stuart C. Gordon9, Paul Kwo10, Jurgen Rockstroh11, Michelle Miller12, Peggy Hwang12, Jacqueline Gress12, Erin Quirk12 1Alamo Medical Research, San Antonio, TX; 2Johns Hopkins Medical Institutions, Baltimore, MD; 3Weill Cornell Medical College, New York, NY; 4Gulf Coast Research, LLC, Baton Rouge, LA; 5Thomas Jefferson University Clinical Research Unit, Philadelphia, PA; 6University of Rochester Medical Center, Rochester, NY;7SNBL Clinical Pharmacology Center, Baltimore, MD; 8The Liver Institute at Methodist Dallas Medical Center, Dallas, TX; 9Henry Ford Hospital, Detroit, MI; 10Indiana University Medical Center, Indianapolis, IN; 11University of Bonn, Department of Medicine, Bonn, Germany; 12Merck & Company, Inc, North Wales, PA
AUTHOR Conclusions
MK-7009 is generally well tolerated at all doses studied -- No dose dependent safety findings
Rapid viral RNA decreases were observed at all doses studied
The greatest HCV RNA declines occurred in the 700 mg b.i.d. dose group -- average decrease of 4.6 log10 IU/mL on Day 8
A Phase IIa study of MK-7009 administered with pegylated-interferon alfa and ribavirin is ongoing.